var data={"title":"Amphotericin B lipid complex: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amphotericin B lipid complex: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5635?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amphotericin-b-lipid-complex-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amphotericin B lipid complex: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-lipid-complex-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amphotericin B lipid complex: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134818\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Abelcet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134819\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abelcet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134840\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134822\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin B liposomal [AmBisome]; amphotericin B cholesteryl sulfate complex [Amphotec]). Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Premedication:</b> For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Usual dose:</b> IV: 5 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer&rsquo;s labeling: Invasive fungal infections</b> (when patients are intolerant or refractory to conventional amphotericin B): IV: 5 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive (salvage therapy):</b> IV: 5 mg/kg/day; minimum duration of treatment is 6 to 12 weeks and depends on site of infection, extent of disease, and level/duration of immunosuppression (IDSA [Patterson 2016]). <b>Note:</b> Amphotericin B lipid complex should be reserved as salvage therapy for those intolerant of or refractory to voriconazole, isavuconazole, or liposomal amphotericin B (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Blastomycosis, moderately severe to severe, non-CNS disease (off-label dose):</b> IV: 3 to 5 mg/kg/day for 1 to 2 weeks or until improvement, followed by oral itraconazole (Chapman 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis (alternative agent) (IDSA [Pappas 2016]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Candidemia (non-neutropenic patients) (off-label dose):</i> 3 to 5 mg/kg/day; may transition to fluconazole (usually after 5 to 7 days) in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures. Total duration of antifungal therapy is at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of candidemia-associated symptoms in patients without metastatic complications. <b>Note:</b> An amphotericin B lipid formation is considered a reasonable alternative agent if there is intolerance, limited availability, or resistance to other antifungals. In patients with suspected azole- and echinocandin-resistant infections, an amphotericin B lipid formulation is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Candidemia (neutropenic patients) (off-label dose):</i> 3 to 5 mg/kg/day; may transition to fluconazole during persistent neutropenia in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures. Total duration of antifungal therapy is at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of neutropenia and candidemia-associated symptoms in patients without metastatic complications. <b>Note:</b> An amphotericin B lipid formation is considered a potential alternative agent, but less attractive option due to its potential for toxicity. However, for infections due to <i>C. krusei</i>, an amphotericin B lipid formulation is a recommended agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic disseminated (hepatosplenic) (off-label dose):</i> 3 to 5 mg/kg/day for several weeks; transition to oral fluconazole in clinically stable patients unlikely to have a fluconazole-resistant isolate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Empiric therapy (non-neutropenic ICU patients) (off-label use): </i> 3 to 5 mg/kg/day; treatment should continue for 14 days in patients with clinical improvement. Consider discontinuing after 4 to 5 days in patients with no clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endocarditis (native or prosthetic valve) or infected implantable cardiac devices (eg, pacemaker, ICD, VAD) (off-label dose):</i> 3 to 5 mg/kg/day (with or without flucytosine); for native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires). <b>Note:</b> May transition to fluconazole if patient clinically stable with fluconazole-susceptible isolates in whom <i>Candida</i> has cleared from the bloodstream.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intra-abdominal candidiasis (off-label dose):</i> 3 to 5 mg/kg/day; duration of therapy determined by clinical response and source control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Osteomyelitis or septic arthritis (alternative therapy) (off-label dose):</i> 3 to 5 mg/kg/day for at least 2 weeks, followed by fluconazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Suppurative thrombophlebitis (off-label dose):</i> 3 to 5 mg/kg/day; continue for at least 2 weeks after candidemia has cleared; consider transition to fluconazole in clinically stable patients with a fluconazole-susceptible isolate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidomycosis, progressive, disseminated (alternative agent) (off-label dose):</b> IV: 2 to 5 mg/kg/day (Galgiani 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidomycosis in HIV-infected patients with severe, nonmeningeal infection (ie, diffuse pulmonary or severely ill with extrathoracic disseminated disease) (off-label use):</b> 3 to 5 mg/kg/day until clinical improvement, then switch to fluconazole or itraconazole (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcosis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cryptococcal meningitis in HIV-infected patients (alternative agent) (off-label use):</i> Induction therapy: 5 mg/kg/day with flucytosine for at least 2 weeks, followed by fluconazole for consolidation therapy (HHS [OI adult 2017]; IDSA [Perfect 2010]). <b>Note:</b> If flucytosine is not given due to intolerance, duration of amphotericin B lipid complex therapy should be 4 to 6 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cryptococcal meningoencephalitis in HIV-negative patients and non-transplant patients (alternative agent):</i> Induction therapy: 5 mg/kg/day (with flucytosine) for &ge;4 weeks followed by oral fluconazole. <b>Note:</b> If flucytosine is not given or treatment is interrupted, consider prolonging induction therapy for an additional 2 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cryptococcal meningoencephalitis in transplant recipients:</i> Induction therapy: 5 mg/kg/day (with flucytosine) for at least 2 weeks, followed by oral fluconazole <b>Note:</b> If flucytosine is not given, duration of amphotericin B lipid complex therapy should be 4 to 6 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nonmeningeal cryptococcosis:</i> Induction therapy: 5 mg/kg/day (with flucytosine) for &ge;4 weeks may be used for severe pulmonary cryptococcosis or for cryptococcemia with evidence of high fungal burden, followed by oral fluconazole. Note: If flucytosine is not given or treatment is interrupted, consider prolonging induction therapy for an additional 2 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Empiric antifungal therapy (neutropenic fever) (alternative agent) (off-label use): </b>IV: 5 mg/kg/day once daily (Wingard 2000). <b>Note:</b> Guidelines recommend amphotericin B lipid formulations be considered for invasive aspergillosis only when triazoles, specifically voriconazole, are contraindicated or not tolerated (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Histoplasmosis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute pulmonary (moderately severe to severe):</i> 5 mg/kg/day for 1 to 2 weeks, followed by oral itraconazole (Wheat 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate to severe disseminated disease in HIV-infected patients (alternative agent) (off-label use):</i> 3 mg/kg/day for at least 2 weeks, followed by itraconazole maintenance therapy (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Progressive disseminated, non-CNS disease (alternative agent):</i> 5 mg/kg/day for 1 to 2 weeks, followed by oral itraconazole (Wheat 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis (visceral) in HIV-infected patients (off-label use): </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment (alternative agent): </i>2 to 4 mg/kg/dose once daily <b>or</b> an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a total dose of 20 to 60 mg/kg (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance therapy (for patients with a CD4 count &lt;200 cells/mm<sup>3</sup>):</i> 3 mg/kg every 21 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sporotrichosis (off-label dose):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningeal:</i> 5 mg/kg/day for 4 to 6 weeks, followed by oral itraconazole (Kauffman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary, osteoarticular, and disseminated:</i> 3 to 5 mg/kg/day, followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy (Kauffman 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134834\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amphotericin-b-lipid-complex-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amphotericin B lipid complex: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin B liposomal [AmBisome]; amphotericin B cholesteryl sulfate complex [Amphotec]). Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Premedication: For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Usual dose:</b> Infants, Children, and Adolescents: IV: 5 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis, treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis</i>\n      <b>:</b> Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Invasive:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily; duration of treatment depends on site of infection, extent of disease, and level of immunosuppression (IDSA [Walsh 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis, invasive:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for initial therapy, usually for 1 to 2 weeks; if CNS infection 4 to 6 weeks may be needed; follow with oral itraconazole for a total of 12 months (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis</i>: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Esophageal: HIV-exposed/-positive:</i> Adolescents: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Invasive (Independent of HIV status):</i> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (IDSA [Pappas 2016]; <b>Note:</b> In HIV-exposed/-positive patients, doses at the higher end of the range may be considered (5 mg/kg/day) (HHS [OI pediatric 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis, invasive: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-infected:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Disseminated infection, nonpulmonary:</i> Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily with or without concomitant azole antifungal therapy (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pulmonary infection, diffuse: </i>Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-infected: <i>Non-CNS infection, severe (ie, diffuse pulmonary or severely ill with extrathoracic, disseminated disease) (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement; dose may be increased to as high as 10 mg/kg/dose once daily for life-threatening infection (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then switch to fluconazole or itraconazole (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated (non-CNS or severe pulmonary disease):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (independent of HIV status): IV: 5 mg/kg/dose once daily; for severe infection in HIV-exposed/-infected patients, may consider the addition of flucytosine (HHS [OI pediatric 2013]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed: IV: 5 mg/kg/dose once daily (with flucytosine) for &ge;4 weeks may be used for severe pulmonary cryptococcosis or for cryptococcemia with evidence of high fungal burden, followed by oral fluconazole. <b>Note:</b> If flucytosine is not given or treatment is interrupted, consider prolonging induction therapy for an additional 2 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IV: Induction therapy: 5 mg/kg/dose once daily with flucytosine for at least 2 weeks, followed by oral fluconazole or itraconazole (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: IV: 5 mg/kg/dose once daily with or without oral flucytosine for a minimum 2-week induction; combination with flucytosine is the preferred treatment (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive (off-label use): IV: 5 mg/kg/dose once daily plus flucytosine or fluconazole; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy; a longer duration of induction therapy may be necessary if CSF is not negative or lack of clinical improvement (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive; nontransplant patients: IV: Induction therapy: 5 mg/kg/dose once daily (with flucytosine) for &ge;4 weeks followed by oral fluconazole; should be used as an alternative to conventional amphotericin B in patients with renal concerns. <b>Note:</b> If flucytosine is not given or treatment is interrupted, consider prolonging induction therapy for an additional 2 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive (off-label use): IV: Induction therapy: 5 mg/kg/dose once daily with flucytosine for at least 2 weeks, followed by fluconazole for consolidation therapy (HHS [OI adult 2016]; IDSA [Perfect 2010]). <b>Note:</b> If flucytosine is not given due to intolerance, duration of amphotericin B lipid complex therapy should be 4 to 6 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Transplant patients: Induction therapy: IV: 5 mg/kg/dose once daily (with flucytosine) for at least 2 weeks followed by oral fluconazole. <b>Note:</b> If flucytosine is not given, duration of therapy should be 4 to 6 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive: <i>Disseminated (non-CNS) or pulmonary disease:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 1 to 2 weeks followed by oral itraconazole for a total of 12 weeks; conventional amphotericin B typically preferred (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive (off-label use): <i>Disseminated disease (moderately severe to severe):</i> Adolescents: IV: 3 mg/kg/dose once daily for at least 2-week induction, followed by oral itraconazole (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis (visceral), HIV-infected patients (off-label use):</b> Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment (alternative agent)</i>: 2 to 4 mg/kg/dose once daily <b>or</b> an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a total dose of 20 to 60 mg/kg (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic maintenance therapy (for patients with a CD4 count &lt;200 cells/mm<sup>3</sup>): </i>3 mg/kg every 21 days (HHS [OI adult 2017])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134823\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134824\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Manufacturer's labeling:</i> No dosage adjustment provided in manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Alternate recommendations (Aronoff 2007):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent hemodialysis: Not hemodialyzable; no supplemental dosage necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peritoneal dialysis: No supplemental dosage necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy (CRRT): No supplemental dosage necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478090\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134799\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abelcet: 5 mg/mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134785\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134802\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For patients who experience nonanaphylactic infusion-related reactions, premedicate 30-60 minutes prior to drug administration with a nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer at an infusion rate of 2.5 mg/kg/hour (eg, over 2 hours for 5 mg/kg). Invert infusion container several times prior to administration and every 2 hours during infusion if it exceeds 2 hours. <b>Do not use an in-line filter during administration.</b> Flush line with dextrose; normal saline may cause precipitate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134801\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Fungal infection (invasive)</b>: Treatment of invasive fungal infection in patients who are refractory to or intolerant of conventional amphotericin B (amphotericin B deoxycholate) therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45497823\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Candidiasis, empiric therapy; Coccidioidomycosis in HIV-infected patients; Cryptococcal meningitis in HIV-infected patients (adolescents and adults); Empiric antifungal therapy (neutropenic fever); Histoplasmosis in HIV-infected patients (adolescents and adults); Leishmaniasis, visceral in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134847\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (Fungizone) or with other lipid-based amphotericin formulations (amphotericin B liposomal [AmBisome]; amphotericin B cholesteryl sulfate complex [Amphotec]) </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134792\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nephrotoxicity and infusion-related hyperpyrexia, rigor, and chilling are reduced relative to amphotericin deoxycholate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (14%), multi-organ failure (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (8%), cardiac arrest (6%), hypertension (5%), chest pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9%), vomiting (8%), diarrhea (6%), abdominal pain (4%), gastrointestinal hemorrhage (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (5%), anemia (4%), leukopenia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (7%), infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory failure (8%), dyspnea (6%), respiratory tract disease (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute hepatic failure, anaphylactoid reaction, anuria, asthma, blood coagulation disorder, brain disease, bronchospasm, cardiac arrhythmia, cardiomyopathy, cerebrovascular accident, cholangitis, cholecystitis, deafness, dysuria, eosinophilia, erythema multiforme, exfoliative dermatitis, extrapyramidal reaction, hearing loss, hematologic disease, hemoptysis, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatitis, hepatomegaly, hepatotoxicity, hypercalcemia, hyperkalemia, hypersensitivity reaction, hypocalcemia, hypomagnesemia, increased blood urea nitrogen, increased serum transaminases, injection site reaction, jaundice, leukocytosis, myasthenia, myocardial infarction, oliguria, peripheral neuropathy, pleural effusion, pulmonary edema, pulmonary embolism, renal insufficiency, renal tubular acidosis, seizure, shock, tachycardia, thrombophlebitis, ventricular fibrillation, vertigo (transient), visual impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134805\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134789\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute reactions (including fever and chills) may occur 1-2 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Infusion has been rarely associated with hypotension, bronchospasm, arrhythmias, and shock.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Disease-related concerns</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antineoplastics: Concurrent use with antineoplastic agents may enhance the potential for renal toxicity, bronchospasm or hypotension; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxic drugs: Concurrent use of amphotericin B with other nephrotoxic drugs may enhance the potential for drug-induced renal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving leukocyte transfusions and amphotericin B; amphotericin B lipid complex and concurrent leukocyte transfusions are not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298745\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134793\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8724&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134795\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314059\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious, systemic fungal diseases in pregnant women, refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmus 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134808\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended by the manufacturer (Mactal-Haaf 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14477892\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">If on parenteral nutrition, may need to adjust the amount of lipid infused. The lipid portion of amphotericin B (lipid complex) formulation contains 0.045 kcal per 5 mg (Sacks 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134797\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN and serum creatinine levels should be determined every other day while therapy is increased and at least weekly thereafter. Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), liver function tests, temperature, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134788\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134804\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Exhibits nonlinear kinetics; volume of distribution and clearance from blood increases with increasing dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: High tissue concentration found in the liver, spleen, and lung ; V<sub>d</sub>: Increases with higher doses (likely reflects increased uptake by tissues); 131 L/kg with 5 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 173 hours following multiple doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: 0.9% of dose excreted in urine over 24 hours; effects of hepatic and renal impairment on drug disposition are unknown</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322988\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Abelcet Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (20 mL): $235.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038525\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abelcet (AE, AR, AT, AU, BB, BE, BR, CR, CY, CZ, DK, DO, ES, FI, FR, GB, GR, GT, HN, HR, HU, IE, IT, LB, LU, NI, NL, NZ, PA, PL, PT, SE, SG, SK, SV, TR);</li>\n      <li>Ampholip (IN, LK, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abelcet (amphotericin lipid complex) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc.; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis; Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &quot;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Marie S, &ldquo;Clinical Use of Liposomal and Lipid-Complexed Amphotericin B,&rdquo; <i>J Antimicrob Chemother</i>, 1994, 33(5):907-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8089064/pubmed\" target=\"_blank\" id=\"8089064\">8089064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards JE Jr, Bodey GP, Bowden RA, et al, &ldquo;International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections,&rdquo; <i>Clin Infect Dis</i>, 1997, 25(1):43-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9243032/pubmed\" target=\"_blank\" id=\"9243032\">9243032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al; Infectious Diseases Society of America. Coccidioidomycosis. <i>Clin Infect Dis</i>. 2005;41(9):1217-1223. doi: 10.1086/496991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hiemenz JW and Walsh TJ, &ldquo;Lipid Formulations of Amphotericin B: Recent Progress and Future Directions,&rdquo; <i>Clin Infect Dis</i>, 1996, 22(Suppl 2):133-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8824978/pubmed\" target=\"_blank\" id=\"8824978\">8824978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hooshmand-Rad R, Chu A, Gotz V, et al, &quot;Use of Amphotericin B Lipid Complex in Elderly Patients,&quot; <i>J Infect</i>, 2005, 50(4):277-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/15845425 /pubmed\" target=\"_blank\" id=\"15845425 \">15845425 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, et al, &quot;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(10):1255-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. <i>Clin Infect Dis</i>. 1998;27(5):1151-1160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9827262/pubmed\" target=\"_blank\" id=\"9827262\">9827262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kline S, Larsen TA, Fieber L, et al, &ldquo;Limited Toxicity of Prolonged Therapy With High Doses of Amphotericin B Lipid Complex,&rdquo; <i>Clin Infect Dis</i>, 1995, 21(5):1154-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8589135/pubmed\" target=\"_blank\" id=\"8589135\">8589135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective agents during lactation, part 3: antivirals, antifungals, and urinary antiseptics.<i> J Hum Lact</i>. 2001;17(2):160-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11847833/pubmed\" target=\"_blank\" id=\"11847833\">11847833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mora-Duarte J, Betts R, Rotstein C, et al, &ldquo;Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,&rdquo; <i>N Engl J Med</i>, 2002, 347(25):2020-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/12490683/pubmed\" target=\"_blank\" id=\"12490683\">12490683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22. doi: 10.1093/jac/dku355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/25204341/pubmed\" target=\"_blank\" id=\"25204341\">25204341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapp RP, Gubbins PO, and Evans ME, &ldquo;Amphotericin B Lipid Complex,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(10):1174-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9337444/pubmed\" target=\"_blank\" id=\"9337444\">9337444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Pappas PG, Karchmer AW, et al, &ldquo;A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole Plus Placebo Versus Fluconazole Plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(10):1221-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/12746765/pubmed\" target=\"_blank\" id=\"12746765\">12746765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks GS and Cleary JD, &ldquo;Nutritional Impact of Lipid-Associated Amphotericin B Formulations,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(1):121-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8997484/pubmed\" target=\"_blank\" id=\"8997484\">8997484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slain D, &ldquo;Lipid-Based Amphotericin B for the Treatment of Fungal Infections,&rdquo; <i>Pharmacotherapy</i>, 1999, 19(3):306-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/10221369/pubmed\" target=\"_blank\" id=\"10221369\">10221369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed September 29, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Anaissie EJ, Denning DW; Infectious Diseases Society of America; et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2008;46(3):327-360. doi: 10.1086/525258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/18177225/pubmed\" target=\"_blank\" id=\"18177225\">18177225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al, &quot;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(7):807-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin Bversus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. LAmph/ABLC Collaborative Study Group. <i>Clin Infect Dis</i>. 2000;31(5):1155-1163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11073745/pubmed\" target=\"_blank\" id=\"11073745\">11073745</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8724 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134818\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134819\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F134840\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F134822\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F134834\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F134823\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F134824\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14478090\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134799\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F134785\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F134802\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F134801\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45497823\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134847\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134792\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134805\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134789\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298745\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134793\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134795\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314059\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F134808\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F14477892\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F134797\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134788\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F134804\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322988\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038525\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8724|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amphotericin-b-lipid-complex-patient-drug-information\" class=\"drug drug_patient\">Amphotericin B lipid complex: Patient drug information</a></li><li><a href=\"topic.htm?path=amphotericin-b-lipid-complex-pediatric-drug-information\" class=\"drug drug_pediatric\">Amphotericin B lipid complex: Pediatric drug information</a></li></ul></div></div>","javascript":null}